RxDoctor Payments Data

Mulugeta Kassahun, MD

Urology · Las Vegas, NVNPI 1922044395

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (54.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $8,798 and has fallen 87.2% since, to $1,127 in 2025.

$12,876in general payments, 2019–2025

Across 61 payments — averaging $211.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Axonics, Inc.$2K
  • Boston Scientific$1K
  • Procept Biorobotics Corporation$1K
  • Urogen Pharma, Inc.$215
  • Medtronic$164
  • plus $485 from 8 others

What the payments were for

  • Travel & lodging$2,37518%
  • Food & beverage$3,50127%
  • Education$7,00054%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,876 in reported general payments places this provider in the 75th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$186,099
Medicare patients
550
Services billed
2,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron82$81,039
Tamsulosin Hcl869$10,559
Finasteride610$6,323
Estradiol53$3,442
Tolterodine Tartrate ErTolterodine Tartrate45$3,160
Alfuzosin Hcl ErAlfuzosin Hcl79$1,563
Oxybutynin Chloride ErOxybutynin Chloride75$1,366
NitrofurantoinNitrofurantoin Macrocrystal52$857
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim310$807
Solifenacin Succinate17$649
Dutasteride24$565
Bicalutamide31$537
Celecoxib42$478
Ciprofloxacin Hcl110$413
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen68$378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$81,03982 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 63 urology providers in Nevada.

Other urology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →